Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Asthma · Respiratory Syncytial Virus Infections

GSK Glaxo Smith

GlaxoSmithKline

GSK Glaxo Smith clinical programs — 70 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
Status
Public
HQ
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
Employees
30
Programs
205
Drugs
194
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

GSK Glaxo Smith projects

70 ClinicalTrials.gov programs sponsored by GSK Glaxo Smith.

GSK Glaxo Smith has 70 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

70 programs

Clinical programs

Page 1 of 2

  1. 0.9% Sodium Chloride Injection

    GlaxoSmithKline

    Non-alcoholic Fatty Liver Disease

    phase 2 small molecule active

    1 trial

  2. 114055

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  3. 200908

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  4. 206882

    GlaxoSmithKline

    Chronic Hepatitis B

    phase 2 other active

    1 trial

  5. 208887

    GlaxoSmithKline

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  6. 209628

    GlaxoSmithKline

    Multiple Myeloma

    phase 2 other active

    1 trial

  7. 213403

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  8. 213824

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  9. 217043

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 small molecule active

    1 trial

  10. 219231

    GlaxoSmithKline

    Hepatitis B

    phase 2 small molecule active

    1 trial

  11. 219590

    GlaxoSmithKline

    Neoplasms

    phase 2 small molecule active

    1 trial

  12. 219867

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  13. 222291

    GlaxoSmithKline

    Liver Diseases, Alcoholic

    phase 2 other active

    1 trial

  14. 222730

    GlaxoSmithKline

    Ovarian Neoplasms

    phase 2 other active

    1 trial

  15. 222892

    GlaxoSmithKline

    MMRp/ MSS colon cancer

    phase 2 small molecule active

    1 trial

  16. 223050

    GlaxoSmithKline

    Neoplasms, Prostate

    phase 2 other active

    1 trial

  17. 223559

    GlaxoSmithKline

    Tumours, Gynecological

    phase 2 small molecule active

    1 trial

  18. 223584

    GlaxoSmithKline

    Myelodysplastic Syndrome

    phase 2 other active

    1 trial

  19. 223646

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 other active

    1 trial

  20. 223675

    GlaxoSmithKline

    Gastrointestinal Neoplasms

    phase 2 other active

    1 trial

  21. 224035

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 other active

    1 trial

  22. 224083

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial

  23. 224317

    GlaxoSmithKline

    Relapsed or Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  24. 300148

    GlaxoSmithKline

    Neoplasms

    phase 2 small molecule active

    1 trial

  25. 300336

    GlaxoSmithKline

    Influenza, Human

    phase 2 small molecule active

    1 trial

  26. 300356

    GlaxoSmithKline

    Influenza, Human

    phase 2 small molecule active

    1 trial

  27. Aprepitant

    GlaxoSmithKline

    Nausea and Vomiting

    phase 2 small molecule completed

    1 trial

  28. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial

  29. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial

  30. DTPw-HBV/Hib-MenAC conjugate vaccine

    GlaxoSmithKline

    Diphtheria

    phase 2 mab completed

    1 trial

  31. Dectova 10 mg/mL solution for infusion

    GlaxoSmithKline

    Influenza, Human

    phase 2 small molecule active

    1 trial

  32. FF/GSK573719

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  33. FF/GW642444M

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  34. Fluticasone Furoate

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  35. Fluticasone furoate (FF) (100 mcg)

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  36. Fluticasone propionate

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  37. GSK Biologicals' GSK2340274A (two different formulations)

    GlaxoSmithKline

    Influenza

    phase 2 mab completed

    1 trial

  38. GSK1070806

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule terminated

    1 trial

  39. GSK221149A

    GlaxoSmithKline

    Obstetric Labour, Premature

    phase 2 small molecule completed

    1 trial

  40. GSK233705 12.5mcg

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  41. GSK256066

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  42. GSK3196165 Dose 1

    GlaxoSmithKline

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  43. GSK4527226

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  44. GSK962040 50 mg

    GlaxoSmithKline

    Gastroparesis

    phase 2 small molecule terminated

    2 trials

  45. GW679769

    GlaxoSmithKline

    Postoperative Nausea and Vomiting

    phase 2 small molecule completed

    1 trial

  46. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  47. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Relapsed/Refractory Tumors

    phase 2 small molecule active

    1 trial

  48. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Rectal

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does GSK Glaxo Smith have?

70 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.